Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Change in Account Payables (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Change in Account Payables for 9 consecutive years, with -$1.1 million as the latest value for Q4 2024.

  • Quarterly Change in Account Payables fell 184.83% to -$1.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2024, down 192.96% year-over-year, with the annual reading at -$535000.0 for FY2025, 74.99% up from the prior year.
  • Change in Account Payables for Q4 2024 was -$1.1 million at SELLAS Life Sciences, up from -$1.8 million in the prior quarter.
  • The five-year high for Change in Account Payables was $1.8 million in Q1 2024, with the low at -$1.8 million in Q3 2024.
  • Average Change in Account Payables over 5 years is -$98700.0, with a median of -$228500.0 recorded in 2020.
  • The sharpest move saw Change in Account Payables tumbled 1897.22% in 2020, then surged 735.92% in 2024.
  • Over 5 years, Change in Account Payables stood at $1.3 million in 2020, then crashed by 131.16% to -$401000.0 in 2021, then soared by 406.73% to $1.2 million in 2022, then rose by 7.15% to $1.3 million in 2023, then tumbled by 184.83% to -$1.1 million in 2024.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$1.1 million, -$1.8 million, and -$1.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.